KCNA3 and diabetes mellitus: The lack of effect of the Kv1.3 blocker is probably not due to insufficient exposure since PAP- plasma trough levels in our study averaged 1.157±0.541 μM (n = 5) and the same PAP-1 dose effectively prevents autoimmune diabetes development in diabetes-prone BB/W rats [10].